1 Introduction Finerenone, a non-steroidal mineralocorticoid receptor antagonist, is indicated to slow kidney disease progression for patients with chronic kidney disease (CKD) and type 2 diabetes (T2DM) [1, 2] and to reduce cardiovascular outcomes among patients with heart failure (HF) and left ventricular ejection fraction (LVEF) ≥ 40% [3].
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile